Compare Organon & Co. (OGN) vs Johnson & Johnson (JNJ) Stock

Organon & Co. (OGN) offers the better valuation at 10.1x trailing P/E (2.1x forward), making it the more compelling value choice. Analysts rate Organon & Co. (OGN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Organon & Co. (OGN) is the cheapest at 10.1x versus Johnson & Johnson at 42.9x. On forward P/E, Organon & Co. is actually cheaper at 2.1x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +70.8%, compared to -65.2% for Organon & Co. (OGN). A $10,000 investment in JNJ five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: JNJ returned +175.7% versus OGN's -65.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Organon & Co.'s 0.92β — meaning OGN is approximately 1557% more volatile than JNJ relative to the S&P 500.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.8% net margin versus 3.0% for Organon & Co. — meaning it keeps 15.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24.9% versus 20.7% for OGN. At the gross margin level — before operating expenses — JNJ leads at 69.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Organon & Co. (OGN) trades at 2.1x forward P/E versus 21.5x for Johnson & Johnson — 19.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: -7.7% to $229.33.

In this comparison, JNJ (2.0% yield) pays a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, OGN: -65.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OGN is a small-cap deep-value stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while OGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.